AbbVie
1 North Waukegan Road
North Chicago
Illinois
60064
United States
Tel: 1-800-255-5162
Website: http://www.abbvie.com/
Email: customerservice@abbvie.com
About AbbVie
AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women’s health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us at www.abbvie.com. Follow @abbvie on Twitter, Facebook, Instagram, and YouTube.
Stock Symbol: ABBV
Stock Exchange: NYSE
We are AbbVie. A global Fortune 500 biopharmaceutical company creating life-changing medicines and first-in-kind solutions that make a real difference in people’s lives.
Our 50,000+ employees across geographies, disciplines, and therapeutic areas put impact at the core of every decision. With over $50B invested in R&D since our founding in 2013, we’re always focused on helping people and communities thrive for generations to come.
1709 articles about AbbVie
-
Big Shot Biotechs Like Eli Lilly, Pfizer, Johnson & Johnson, and AbbVie Bet $48 Million on Startup Petra Pharma
1/7/2016
-
AbbVie's HUMIRA (Adalimumab) Receives First And Only Health Canada Approval For Moderate To Severe Hidradenitis Suppurativa
1/6/2016
-
Analyzing Gilead's Gamble on a Drug Both AbbVie and Johnson & Johnson Gave Up On
1/4/2016
-
The Medicines Patent Pool And AbbVie Sign Licensing Agreement To Increase Access To Crucial HIV Treatments Throughout Africa
12/18/2015
-
AbbVie To Present At The 34th Annual J.P. Morgan Healthcare Conference
12/16/2015
-
AbbVie Reveals Positive CLL Data at American Society of Hematology
12/7/2015
-
AbbVie Reports Phase 2 Results Of Venetoclax In Relapsed/Refractory Chronic Lymphocytic Leukemia Patients With 17p Deletion
12/7/2015
-
AbbVie Release: IMBRUVICA (Ibrutinib) Phase 3 RAY Data Show Significant Reductions In Disease Progression Versus Temsirolimus In Relapsed/Refractory Mantle Cell Lymphoma Patients
12/7/2015
-
AbbVie Release: Ibrutinib (IMBRUVICA) Improves Survival In Treatment-Naive Chronic Lymphocytic Leukemia Patients In The Phase 3 RESONATE-2 Trial
12/7/2015
-
AbbVie Release: Ibrutinib (IMBRUVICA) Combination Data Show Promise In Patients With Relapsed/Refractory Multiple Myeloma
12/7/2015
-
AbbVie Release: Combination Ibrutinib (IMBRUVICA) Demonstrates A Strong Response Rate In Treatment-Naive Patients With Follicular Lymphoma
12/7/2015
-
AbbVie Announces The New England Journal of Medicine Online Publication Of Venetoclax Phase 1 Data In Relapsed/Refractory Chronic Lymphocytic Leukemia
12/7/2015
-
AbbVie Launches Crohn's & Colitis Scholarship To Support Students Living With Inflammatory Bowel Disease
12/4/2015
-
Enanta Pharmaceuticals, Inc. Announces FDA Acceptance Of AbbVie’s New Drug Application For A Once-Daily Formulation Of VIEKIRA PAK For The Treatment Of Genotype 1 Chronic Hepatitis C Virus Infection
12/2/2015
-
AbbVie Announces FDA Acceptance Of New Drug Application For A Once-Daily Formulation Of VIEKIRA PAK (ombitasvir, paritaprevir, and ritonavir tablets; dasabuvir tablets) To Treat Genotype 1 Chronic Hepatitis C Virus Infection
12/2/2015
-
Bristol-Myers Squibb And AbbVie Receive FDA Approval Of Empliciti (Elotuzumab) For The Treatment Of Patients With Multiple Myeloma Who Have Received One To Three Prior Therapies
12/1/2015
-
AbbVie Launches Good Morning Hypothyroidism To Help Hypothyroid Patients Manage Their Life-Long Condition Through Education And A Sense Of Community
11/30/2015
-
AbbVie's VIEKIRA PAK Shows 95% Cure Rate in as Little as 12 Weeks in Phase III Hepatitis C Study
11/16/2015
-
AbbVie Announces High Sustained Virologic Response Rates In Phase 2 Studies With Pan-Genotypic, Investigational Regimen In Patients With Chronic Hepatitis C
11/16/2015
-
AbbVie Submits IMBRUVICA (ibrutinib) Phase III Combination Data To U.S. FDA
11/13/2015